Walgreens Boots Alliance, Inc. (0LSZ.L)
USD 10.22
(-7.23%)
USD 10.22
(-7.23%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 8.04 Billion USD | -1.24% |
| 2023 | 30.26 Billion USD | -5.8% |
| 2022 | 32.13 Billion USD | 7.72% |
| 2021 | 29.82 Billion USD | -12.72% |
| 2020 | 34.17 Billion USD | 207.95% |
| 2019 | 11.09 Billion USD | -10.72% |
| 2018 | 12.43 Billion USD | -1.99% |
| 2017 | 12.68 Billion USD | -32.19% |
| 2016 | 18.7 Billion USD | 40.48% |
| 2015 | 13.31 Billion USD | 256.4% |
| 2014 | 3.73 Billion USD | -16.55% |
| 2013 | 4.47 Billion USD | 9.92% |
| 2012 | 4.07 Billion USD | 69.99% |
| 2011 | 2.39 Billion USD | 0.29% |
| 2010 | 2.38 Billion USD | 2.27% |
| 2009 | 2.33 Billion USD | 74.69% |
| 2008 | 1.33 Billion USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| 1994 | - USD | 0.0% |
| 1993 | - USD | -100.0% |
| 1992 | 18.7 Million USD | -84.8% |
| 1991 | 123 Million USD | -16.16% |
| 1990 | 146.7 Million USD | -2.27% |
| 1989 | 150.1 Million USD | -12.78% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 7.4 Billion USD | -1.7% |
| 2024 Q1 | 29.71 Billion USD | -6.88% |
| 2024 Q4 | 8.04 Billion USD | 8.6% |
| 2024 Q2 | 7.53 Billion USD | -0.66% |
| 2023 Q2 | 31.01 Billion USD | 5.84% |
| 2023 FY | 30.26 Billion USD | -5.8% |
| 2023 Q1 | 29.3 Billion USD | -8.8% |
| 2023 Q3 | 31.02 Billion USD | 0.02% |
| 2023 Q4 | 30.26 Billion USD | -2.43% |
| 2022 FY | 32.13 Billion USD | 7.72% |
| 2022 Q4 | 32.13 Billion USD | -0.28% |
| 2022 Q2 | 33.15 Billion USD | -0.44% |
| 2022 Q1 | 33.3 Billion USD | 11.65% |
| 2022 Q3 | 32.22 Billion USD | -2.81% |
| 2021 Q3 | 29.82 Billion USD | -10.0% |
| 2021 Q4 | 29.82 Billion USD | 0.03% |
| 2021 Q1 | 33.13 Billion USD | -3.03% |
| 2021 Q2 | 33.13 Billion USD | -0.02% |
| 2021 FY | 29.82 Billion USD | -12.72% |
| 2020 FY | 34.17 Billion USD | 207.95% |
| 2020 Q1 | 32.52 Billion USD | 193.05% |
| 2020 Q2 | 32.58 Billion USD | 0.19% |
| 2020 Q3 | 34.05 Billion USD | 4.51% |
| 2020 Q4 | 34.17 Billion USD | 0.36% |
| 2019 FY | 11.09 Billion USD | -10.72% |
| 2019 Q3 | 12.12 Billion USD | -4.4% |
| 2019 Q4 | 11.09 Billion USD | -8.49% |
| 2019 Q2 | 12.68 Billion USD | 8.92% |
| 2019 Q1 | 11.64 Billion USD | -6.31% |
| 2018 FY | 12.43 Billion USD | -1.99% |
| 2018 Q1 | 12.73 Billion USD | 0.42% |
| 2018 Q2 | 12.53 Billion USD | -1.61% |
| 2018 Q3 | 12.45 Billion USD | -0.61% |
| 2018 Q4 | 12.43 Billion USD | -0.2% |
| 2017 Q1 | 17.77 Billion USD | -4.96% |
| 2017 FY | 12.68 Billion USD | -32.19% |
| 2017 Q4 | 12.68 Billion USD | -11.75% |
| 2017 Q3 | 14.37 Billion USD | -19.07% |
| 2017 Q2 | 17.75 Billion USD | -0.11% |
| 2016 Q3 | 13.15 Billion USD | 1.36% |
| 2016 Q2 | 12.97 Billion USD | -1.67% |
| 2016 FY | 18.7 Billion USD | 40.48% |
| 2016 Q4 | 18.7 Billion USD | 42.23% |
| 2016 Q1 | 13.19 Billion USD | -0.91% |
| 2015 Q4 | 13.31 Billion USD | -11.56% |
| 2015 Q2 | 16 Billion USD | 16.32% |
| 2015 Q1 | 13.75 Billion USD | 268.2% |
| 2015 FY | 13.31 Billion USD | 256.4% |
| 2015 Q3 | 15.05 Billion USD | -5.91% |
| 2014 Q1 | 4.5 Billion USD | 0.54% |
| 2014 Q4 | 3.73 Billion USD | -0.29% |
| 2014 Q3 | 3.74 Billion USD | -16.53% |
| 2014 Q2 | 4.48 Billion USD | -0.27% |
| 2014 FY | 3.73 Billion USD | -16.55% |
| 2013 FY | 4.47 Billion USD | 9.92% |
| 2013 Q4 | 4.47 Billion USD | -0.53% |
| 2013 Q3 | 4.5 Billion USD | -11.01% |
| 2013 Q2 | 5.05 Billion USD | -0.22% |
| 2013 Q1 | 5.06 Billion USD | 24.45% |
| 2012 Q1 | 2.39 Billion USD | -0.25% |
| 2012 FY | 4.07 Billion USD | 69.99% |
| 2012 Q4 | 4.07 Billion USD | 70.63% |
| 2012 Q3 | 2.38 Billion USD | 0.25% |
| 2012 Q2 | 2.38 Billion USD | -0.38% |
| 2011 Q3 | 2.38 Billion USD | 0.17% |
| 2011 Q4 | 2.39 Billion USD | 0.5% |
| 2011 Q1 | 2.38 Billion USD | 0.0% |
| 2011 Q2 | 2.38 Billion USD | -0.38% |
| 2011 FY | 2.39 Billion USD | 0.29% |
| 2010 Q2 | 2.34 Billion USD | -0.8% |
| 2010 FY | 2.38 Billion USD | 2.27% |
| 2010 Q1 | 2.36 Billion USD | 1.28% |
| 2010 Q4 | 2.38 Billion USD | 1.27% |
| 2010 Q3 | 2.35 Billion USD | 0.51% |
| 2009 Q4 | 2.33 Billion USD | -0.09% |
| 2009 FY | 2.33 Billion USD | 74.69% |
| 2009 Q1 | 1.33 Billion USD | -0.01% |
| 2009 Q2 | 2.33 Billion USD | 74.42% |
| 2009 Q3 | 2.33 Billion USD | 0.26% |
| 2008 Q2 | - USD | 0.0% |
| 2008 FY | 1.33 Billion USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q4 | 1.33 Billion USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1995 Q1 | - USD | 0.0% |
| 1995 Q3 | - USD | 0.0% |
| 1995 Q2 | - USD | 0.0% |
| 1995 Q4 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| 1994 Q2 | - USD | 0.0% |
| 1994 Q4 | - USD | 0.0% |
| 1994 Q3 | - USD | 0.0% |
| 1994 FY | - USD | 0.0% |
| 1994 Q1 | - USD | 0.0% |
| 1993 Q1 | 19.1 Million USD | 2.14% |
| 1993 Q4 | - USD | -100.0% |
| 1993 Q3 | 8.8 Million USD | -36.69% |
| 1993 FY | - USD | -100.0% |
| 1993 Q2 | 13.9 Million USD | -27.23% |
| 1992 FY | 18.7 Million USD | -84.8% |
| 1992 Q1 | 122.7 Million USD | -0.24% |
| 1992 Q2 | 118.8 Million USD | -3.18% |
| 1992 Q3 | 118.8 Million USD | 0.0% |
| 1992 Q4 | 18.7 Million USD | -84.26% |
| 1991 Q3 | 134.8 Million USD | 0.0% |
| 1991 Q1 | 146.5 Million USD | -0.14% |
| 1991 FY | 123 Million USD | -16.16% |
| 1991 Q2 | 134.8 Million USD | -7.99% |
| 1991 Q4 | 123 Million USD | -8.75% |
| 1990 Q4 | 146.7 Million USD | -1.15% |
| 1990 FY | 146.7 Million USD | -2.27% |
| 1990 Q3 | 148.4 Million USD | 0.0% |
| 1990 Q2 | 148.4 Million USD | -0.93% |
| 1990 Q1 | 149.8 Million USD | -0.2% |
| 1989 FY | 150.1 Million USD | -12.78% |
| 1989 Q4 | 150.1 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | -6084.6% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -14015.252% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | -1973.955% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -17504.447% |
| bluebird bio, Inc. | 224.41 Million USD | -3484.367% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -21594.22% |
| Imunon, Inc. | 1.13 Million USD | -705951.911% |
| Editas Medicine, Inc. | 24.37 Million USD | -32905.088% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 37.908% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | -307.178% |
| Myriad Genetics, Inc. | 130.9 Million USD | -6045.149% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -3014.208% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -24131.835% |
| Verastem, Inc. | 40.08 Million USD | -19966.856% |
| Waters Corporation | 2.3 Billion USD | -248.903% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 74.307% |
| Biogen Inc. | 7.18 Billion USD | -11.906% |
| Nektar Therapeutics | 112.62 Million USD | -7042.286% |
| Perrigo Company plc | 3.63 Billion USD | -121.427% |
| Dynavax Technologies Corporation | 252.41 Million USD | -3086.777% |
| Illumina, Inc. | 1.48 Billion USD | -440.228% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -248276.552% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -804300.0% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -4529.56% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -34073.074% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | -1256.275% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -23901.193% |
| Evolus, Inc. | 120.35 Million USD | -6583.339% |
| Adicet Bio, Inc. | 17.7 Million USD | -45338.626% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -261578.595% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | -197.606% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | -1503.841% |
| FibroGen, Inc. | 89.69 Million USD | -8867.97% |
| Agilent Technologies, Inc. | 2.73 Billion USD | -194.113% |
| OPKO Health, Inc. | 222.03 Million USD | -3522.869% |
| Homology Medicines, Inc. | 43.17 Million USD | -18530.721% |
| Geron Corporation | 35.05 Million USD | -22849.417% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | -243.317% |
| Exelixis, Inc. | 189.94 Million USD | -4134.932% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -859301.709% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -8214.47% |
| Zoetis Inc. | 6.56 Billion USD | -22.547% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -4417.325% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -182635.12% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | -1009.977% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -23427.347% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | -474.417% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | -610.278% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | -436.536% |
| Blueprint Medicines Corporation | 610.96 Million USD | -1216.612% |
| Insmed Incorporated | 1.19 Billion USD | -574.068% |
| TG Therapeutics, Inc. | 100.11 Million USD | -7934.519% |
| Incyte Corporation | 29.16 Million USD | -27483.842% |
| Emergent BioSolutions Inc. | 446.5 Million USD | -1701.568% |